Skip to main content
SpringerLink
Log in

A Benefit-Risk Assessment of Extended-Release Oxybutynin

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth.

An extended-release (ER) formulation of oxybutynin based on the OROS®1 system has recently become available, which allows once daily administration.

In direct comparison to oxybutynin IR, oxybutynin ER has an increased oral bioavailability for the parent compound oxybutynin which is accompanied by a reduced bioavailability for the active metabolite N-desethyl-oxybutynin. The latter has been implicated in mediating a major part of the adverse effects of oxybutynin treatment.

Two double-blind, placebo-controlled, randomised studies in patients with overactive bladder have demonstrated that oxybutynin ER has a similar efficacy as oxybutynin IR but with improved tolerability. This is in line with clinical pharmacological studies demonstrating a smaller impairment of saliva production with oxybutynin ER than with oxybutynin IR.

Thus, the ER formulation of oxybutynin maintains the therapeutic benefits and concomitantly improves tolerability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Hunskaar S, Arnold EP, Burgio K, et al. Epidemiology and natural history of urinary incontinence (UI). In: Abrams P, Khoury S, Wein A, editors. Incontinence. Plymouth: Plymbridge Distributors Ltd, 1999: 197–226

    Google Scholar 

  2. Goepel M, Hoffmann J, Piro M, et al. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol 2002; 41: 234–9

    Article  PubMed  Google Scholar 

  3. Bulmer P, Abrams P. The overactive bladder. Rev Contemp Pharmacother 2000; 11: 1–11

    Google Scholar 

  4. Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135–40

    Article  PubMed  CAS  Google Scholar 

  5. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? a population-based prevalence study. BJU Int 2001; 87: 760–6

    Article  PubMed  CAS  Google Scholar 

  6. Luscombe FA. Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment. Rev Contemp Pharmacother 2000; 11: 43–62

    Google Scholar 

  7. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253–308

    Google Scholar 

  8. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55Suppl. 5A: 33–46

    Article  PubMed  CAS  Google Scholar 

  9. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243–62

    Article  PubMed  CAS  Google Scholar 

  10. Andersson K-E, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001; 19: 319–23

    Article  PubMed  CAS  Google Scholar 

  11. Malone-Lee JG. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder. Rev Contemp Pharmacother 2000; 11: 29–42

    CAS  Google Scholar 

  12. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39: 289–96

    PubMed  CAS  Google Scholar 

  13. Sathyan G, Chancellor MB, Gupta SK. Effects of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 52: 409–17

    Article  PubMed  CAS  Google Scholar 

  14. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000; 16: 149–55

    Article  PubMed  CAS  Google Scholar 

  15. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515–20

    Article  PubMed  CAS  Google Scholar 

  16. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859–69

    Article  PubMed  CAS  Google Scholar 

  17. Caulfield MP, Birdsall NJ. International Union of Pharmacology: XVII. classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279–90

    PubMed  CAS  Google Scholar 

  18. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: 959–66

    PubMed  CAS  Google Scholar 

  19. Goepel M, Gronewald A, Krege S, et al. Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urol Res 1998; 26: 149–54

    Article  PubMed  CAS  Google Scholar 

  20. Yamanishi T, Chapple CR, Yasuda K, et al. The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol 2000; 131: 1482–8

    Article  PubMed  CAS  Google Scholar 

  21. Hegde SS, Choppin A, Bonhaus D, et al. Functional role ofM2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997; 120: 1409–18

    Article  PubMed  CAS  Google Scholar 

  22. Choppin A, Eglen RM, Hegde SS. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol 1998; 124: 883–8

    Article  PubMed  CAS  Google Scholar 

  23. Fetscher C, Fleichman M, Schmidt M, et al. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136: 641–4

    Article  PubMed  CAS  Google Scholar 

  24. Tobin G. Muscarinic receptor subtypes in the submandibular gland and the urinary bladder of the rabbit: in vivo and in vitro functional comparisons of receptor antagonists. J Auton Pharmacol 1995; 15: 451–63

    Article  PubMed  CAS  Google Scholar 

  25. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531–65

    PubMed  CAS  Google Scholar 

  26. Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 2001; 132: 835–42

    Article  PubMed  CAS  Google Scholar 

  27. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157: 1093–7

    Article  PubMed  CAS  Google Scholar 

  28. Madersbacher H, Knoll M. Intravesical application of oxybutynin: mode of action controlling detrusor hypereflexia: preliminary results. Eur Urol 1995; 28: 340–4

    PubMed  CAS  Google Scholar 

  29. Di Stasi SM, Giannantoni A, Navarra P, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl-oxybutynin. J Urol 2001; 166: 2232–6

    Article  PubMed  Google Scholar 

  30. Yong C-L, Yu D, Eden L, et al. Effect of food on the pharmacokinetics of oxybutynin in normal subjects [abstract]. Pharm Res 1991; 8Suppl.: S–320

    Google Scholar 

  31. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988; 140: 47–50

    PubMed  CAS  Google Scholar 

  32. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 1809–12

    Article  PubMed  CAS  Google Scholar 

  33. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718–21

    Article  PubMed  CAS  Google Scholar 

  34. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 420–3

    Article  PubMed  CAS  Google Scholar 

  35. Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 2002; 59: 428–32

    Article  PubMed  Google Scholar 

  36. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185: 56–61

    Article  PubMed  CAS  Google Scholar 

  37. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414–21

    Article  PubMed  Google Scholar 

  38. Chancellor MB, Appell RA, Sathyan G, et al. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001; 23: 753–60

    Article  PubMed  CAS  Google Scholar 

  39. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358–63

    PubMed  CAS  Google Scholar 

  40. Sussman D. Dry mouth is more pronounced in patients with overactive bladder treated with extended release oxybutynin compared to tolterodine [abstract]. Eur Urol Suppl 2002; 1: 133

    Article  Google Scholar 

Download references

Acknowledgements

The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Essen, Essen, 45122, Germany

    Martin C. Michel

Authors
  1. Martin C. Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin C. Michel.

Additional information

The use of tradenames is for product identification purposes only and does not imply endorsement.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michel, M.C. A Benefit-Risk Assessment of Extended-Release Oxybutynin. Drug-Safety 25, 867–876 (2002). https://doi.org/10.2165/00002018-200225120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225120-00004

Keywords

Search

Navigation